MDM2

MDM2
Name	MDM2
Organism	Homo sapiens

MDM2 MDM2 is an E3 ubiquitin-protein ligase that negatively regulates the tumor suppressor p53 and controls cellular responses to stress. It participates in feedback loops with p53, interfaces with multiple signaling nodes including the PI3K/AKT pathway and MAPK pathway, and influences processes studied across fields from Oncology to Cell biology and Molecular biology. Prominent research groups at institutions such as National Institutes of Health, Cold Spring Harbor Laboratory, Harvard University, and Stanford University have illuminated its centrality to cancer biology and therapeutic development.

Function and Mechanism

MDM2 functions primarily as an E3 ubiquitin ligase targeting p53 for ubiquitination and proteasomal degradation, thereby modulating apoptosis, cell cycle arrest, and DNA repair. It establishes an autoregulatory feedback loop with p53 akin to regulatory motifs described in systems from Janus-faced regulation to classic negative feedback exemplified in studies at Max Planck Society and Broad Institute. Through ubiquitination, it influences pathways also regulated by MDM4 and interfaces with kinases such as ATM, ATR, CHK1, and CHK2, integrating DNA damage responses characterized in landmark work at Cold Spring Harbor Laboratory and Dana-Farber Cancer Institute.

Structure and Domains

The protein contains an N-terminal p53-binding domain structurally reminiscent of ubiquitin ligases characterized by groups at European Molecular Biology Laboratory and Scripps Research. It includes a central acidic domain, a zinc finger domain, and a C-terminal RING finger that mediates E2 enzyme recruitment and ubiquitin transfer, features elucidated with contributions from EMBL-EBI and structural studies at Rutherford Appleton Laboratory. Comparative structural analyses cite methods developed at Max Planck Institute for Biochemistry and cryo-EM advances from MRC Laboratory of Molecular Biology.

Regulation and Post-translational Modifications

MDM2 is regulated by phosphorylation, acetylation, SUMOylation, and ubiquitination, with modifications imposed by kinases and ligases such as AKT1, CK1, GSK3B, CBP, and P300. These post-translational modifications alter interactions with p53, with regulators and readers studied at Yale University, Columbia University, and University of Cambridge. DNA damage sensors including ATM and ATR phosphorylate components of the axis in paradigms outlined in work at Rockefeller University and Johns Hopkins University, shifting MDM2 activity and cellular fate decisions central to tumor suppression research at Memorial Sloan Kettering Cancer Center.

Role in Cancer and Disease

Overexpression, amplification, or aberrant regulation of MDM2 contributes to oncogenesis in contexts such as sarcoma, glioblastoma, and liposarcoma, reported in clinical series from Mayo Clinic, MD Anderson Cancer Center, and University of Texas MD Anderson Cancer Center. Its dysregulation undermines p53-mediated checkpoints, paralleling mutations catalogued by projects such as The Cancer Genome Atlas and initiatives at International Agency for Research on Cancer. Beyond cancer, MDM2 involvement has been implicated in ischemia-reperfusion injury and metabolic disorders investigated at Cleveland Clinic and by consortia including European Society for Clinical Investigation.

Interactions and Pathways

MDM2 interacts with a broad network including p53, MDM4, RB1, E2F1, ARF, USP7, and components of the ubiquitin-proteasome system characterized at Proteasome Research Center and through collaborations with EMBL. It modulates signaling through the PI3K/AKT pathway, cross-talks with MAPK pathway effectors, and affects transcriptional programs governed by factors like NF-κB, MYC, and STAT3. The interaction map reflects datasets from consortia such as Human Protein Atlas and pathway curation efforts at Reactome and KEGG.

Clinical Significance and Therapeutic Targeting

MDM2 is a target for small molecules and biologics aiming to reactivate p53 in cancers retaining wild-type p53. Clinical candidates and inhibitors such as Nutlin-class compounds, spiro-oxindoles, and stapled peptides have advanced through trials at centers including National Cancer Institute, GlaxoSmithKline, Roche, and Novartis. Biomarker strategies rely on genomic profiling from The Cancer Genome Atlas and companion diagnostics developed in partnerships with academic centers like UCSF and Imperial College London. Resistance mechanisms involving amplification, mutation, or pathway rerouting are topics of investigation across translational programs at Fred Hutchinson Cancer Research Center and Vanderbilt University Medical Center.

Category:Proteins Category:Oncogenes